BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11189505)

  • 21. Thyroid dysfunction after bone marrow transplantation for primary immunodeficiency without the use of total body irradiation in conditioning.
    Slatter MA; Gennery AR; Cheetham TD; Bhattacharya A; Crooks BN; Flood TJ; Cant AJ; Abinun M
    Bone Marrow Transplant; 2004 May; 33(9):949-53. PubMed ID: 15004542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study.
    Choi SJ; Lee JH; Lee JH; Kim S; Lee YS; Seol M; Ryu SG; Lee JS; Kim WK; Jang S; Park CJ; Chi HS; Lee KH
    Bone Marrow Transplant; 2005 Jul; 36(2):163-9. PubMed ID: 15937507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hematopoietic stem cell transplantation with busulfanthiotepa-cyclophosphamide conditioning for pediatric patients with high-risk acute lymphoblastic leukemia].
    Umeda K; Lin YW; Watanabe K; Adachi S; Usami I; Akiyama Y; Kubota M; Nakahata T
    Rinsho Ketsueki; 2001 Sep; 42(9):685-90. PubMed ID: 11680979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
    Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
    Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term results of allogeneic bone marrow transplantation for 108 adult patients with acute lymphoblastic leukemia: favorable outcome with BMT at first remission and HLA-matched unrelated donor.
    Chim CS; Lie AK; Liang R; Au WY; Kwong YL
    Bone Marrow Transplant; 2007 Aug; 40(4):339-47. PubMed ID: 17572712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
    Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
    Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched-related and matched-unrelated donor transplants.
    Al-Kasim FA; Thornley I; Rolland M; Lau W; Tsang R; Freedman MH; Saunders EF; Calderwood S; Doyle JJ
    Br J Haematol; 2002 Feb; 116(2):483-90. PubMed ID: 11841456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
    Giebel S; Krawczyk-Kulis M; Adamczyk-Cioch M; Jakubas B; Palynyczko G; Lewandowski K; Dmoszynska A; Skotnicki A; Nowak K; Holowiecki J;
    Ann Hematol; 2006 Oct; 85(10):717-22. PubMed ID: 16832677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth and endocrine function in children with acute myeloid leukaemia after bone marrow transplantation using busulfan/cyclophosphamide.
    Afify Z; Shaw PJ; Clavano-Harding A; Cowell CT
    Bone Marrow Transplant; 2000 May; 25(10):1087-92. PubMed ID: 10828870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
    Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB
    Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late thyroid toxicity in 153 long-term survivors of allogeneic bone marrow transplantation for acute lymphoblastic leukaemia.
    Berger C; Le-Gallo B; Donadieu J; Richard O; Devergie A; Galambrun C; Bordigoni P; Vilmer E; Plouvier E; Perel Y; Michel G; Stephan JL
    Bone Marrow Transplant; 2005 May; 35(10):991-5. PubMed ID: 15806126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Unrelated donor allogenetic marrow transplantation in treatment of acute and chronic leukemia].
    Huang H; Lin M; Meng H
    Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):263-7. PubMed ID: 11798883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone marrow transplantation in children with severe aplastic anemia using a conditioning regimen containing 3 Gy of total body irradiation, cyclophosphamide with or without antithymocyte globulin.
    Inagaki J; Nagatoshi Y; Kawano Y; Saito Y; Takahashi D; Nagayama J; Shinkoda Y; Hirata H; Okamura J
    Pediatr Transplant; 2007 Mar; 11(2):180-6. PubMed ID: 17300498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation.
    Zenz T; Schlenk RF; Glatting G; Neumaier B; Blumstein N; Buchmann I; von Harsdorf S; Ringhoffer M; Wiesneth M; Keller F; Kotzerke J; Röttinger E; Stilgenbauer S; Döhner H; Reske SN; Bunjes D
    J Nucl Med; 2006 Feb; 47(2):278-86. PubMed ID: 16455634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disease- or therapy-related bone marrow damage cannot be overcome by changes in stem cell source or dose in allogeneic transplantation.
    Novotny JR; Rosenthal C; Elmaagacli AH; Dürig J; Beelen DW; Dührsen U
    Eur J Haematol; 2004 Jul; 73(1):1-9. PubMed ID: 15182331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone marrow transplantation from unrelated donors for patients with adult T-cell leukaemia/lymphoma.
    Nakase K; Hara M; Kozuka T; Tanimoto K; Nawa Y
    Bone Marrow Transplant; 2006 Jan; 37(1):41-4. PubMed ID: 16247419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A second allogeneic transplantation with a mild conditioning regimen in a patient with a posttransplantation relapse of lymphoblastic lymphoma after achieving aplasia with Daunoxome and alkeran].
    Obukhova EE; Melkova KN; Tugova SV; Konchalovskiĭ MV; Baranov AE
    Ter Arkh; 2000; 72(7):68-9. PubMed ID: 10983327
    [No Abstract]   [Full Text] [Related]  

  • 39. Bone marrow transplantation for advanced acute lymphoblastic leukemia in young people: a comparison of two conditioning regimens.
    Graham-Pole J; Elfenbein G; Gross S; Higby D; Marcus R; O'Leary M; Weiner R
    Bone Marrow Transplant; 1987 Jun; 2(1):85-9. PubMed ID: 3332160
    [No Abstract]   [Full Text] [Related]  

  • 40. Constrictive pericarditis post allogeneic bone marrow transplant for Philadelphia-positive acute lymphoblastic leukaemia.
    Cavet J; Lennard A; Gascoigne A; Finney RD; Lucraft HH; Richardson C; Taylor PR; Proctor SJ; Jackson GH
    Bone Marrow Transplant; 2000 Mar; 25(5):571-3. PubMed ID: 10713638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.